DIRS.INFO The most relevant business & tech news

☆ Austria outclass Euro 2024 hosts Germany in 2-0 win
▼ + stars: | 2023-11-21 | by ( ) www.reuters.com time to read: +2 min

VIENNA, Nov 21 (Reuters) - Austria outplayed a toothless Germany to win 2-0 in their friendly on Tuesday, ending their year on a high while piling more pressure on the embattled Euro 2024 hosts who had Leroy Sane sent off early in the second half. Marcel Sabitzer's low drive in the 29th minute put the dominant hosts, who have qualified for the Euros, in front with Germany posing no threat in attack and needing 32 minutes for their first shot on goal. Austria shot out of the blocks and overwhelmed the error-prone Germans with a high-pressing game. While the hosts carved out several chances, including a golden opportunity for Michael Gregoritsch who failed to beat Trapp when one-on-one, Germany had to wait 32 minutes for their first effort towards goal. Germany's disappointing evening was complete when Baumgartner added a second goal, with Austria missing more chances late in the game.

Persons: Leroy Sane, Marcel Sabitzer's, Austria's Christoph Baumgartner, Kevin Trapp, Julian Nagelsmann, Nagelsmann, Michael Gregoritsch, Trapp, Thomas Mueller, Sane, Phillipp, Baumgartner, Karolos, Toby Davis Organizations: Thomson Locations: VIENNA, Austria, Germany, Turkey

Youngest brother Ted Kennedy was elected to John F. Kennedy's former Senate seat in Massachusetts. Ted Kennedy became a revered liberal voice and legislator, while Shriver was chosen as George McGovern's running mate in their unsuccessful 1972 presidential campaign. The last of President Kennedy's surviving siblings, former U.S. ambassador to Ireland Jean Smith, died in 2020. Robert F. Kennedy's widow, Ethel, is in her 90s and rarely comments publicly. Starting in 1968, after the assassination of Robert Kennedy, Ted Kennedy was the family's standard bearer and chosen orator.

Persons: — Patrick Kennedy, Sen, Ted Kennedy, John F, Kennedy, “, Republican David Dumas, ’, Patrick Kennedy, President Kennedy, Robert F, Kennedy Jr, Kerry Kennedy, Jack Schlossberg, ”, Thurston Clarke, Robert . “, Clarke, Robert Kennedy Jr, Patrick, John Francis “ Honey Fitz ” Fitzgerald, JFK's, Robert Kennedy, Sargent Shriver, Stephen Smith, Jacqueline Kennedy's, Shriver, George McGovern's, Joseph Kennedy II, Robert's, Kathleen Kennedy Townsend, Arnold Schwarzenegger, Maria Shriver, Caroline Kennedy, Hillary Clinton, Clinton, Barack Obama, David Paterson, Sean Wilentz, ” Patrick Kennedy, Amy, —, Richard Goodwin, Kennedy's, Ireland Jean Smith, Ethel, Caroline’s, Obama, Biden, Julian E, Zelizer, Robert, Robert Jr, ” Robert F, Caroline, Joseph Kennedy III, Victoria Reggie Kennedy, Ted Kennedy's, ” Timothy Shriver, Eunice Shriver, Kerry's, Rory Kennedy, Larry Sabato, hasn’t, “ I've Organizations: Republican, JFK, Boston Mayor, Peace Corps, White House, Senate, New York Gov, White, RFK Jr, Progress, Mental Health, RFK Human Rights Locations: Rhode Island, Massachusetts, Maryland, U.S, Ireland, Japan, Australia, Northern Ireland, Austria, Mississippi, Iraq

☆ Bayer stops blood thinner drug trial due to lack of effect, in major setback
▼ + stars: | 2023-11-20 | by ( Ludwig Burger | ) www.reuters.com time to read: +3 min

Logo and flags of Bayer AG are pictured outside a plant of the German pharmaceutical and chemical maker in Wuppertal, Germany August 9, 2019. REUTERS/Wolfgang Rattay/File Photo Acquire Licensing RightsNov 19 (Reuters) - Germany's Bayer (BAYGn.DE) has aborted a large late-stage trial testing a new anti-clotting drug due to lack of efficacy, dealing a fresh blow to the embattled drugmaker and throwing its most promising medium-term development project in doubt. The trial halt, which followed recommendation of independent trial supervisors, marks another setback for a company burdened by a weak herbicide business, high debt and by U.S. lawsuits over the alleged carcinogenic effect of its commonly used Roundup weedkiller. Bayer said it will further analyse the data of the discontinued trial, known as OCEANIC-AF, which was initiated in August 2022. It said the independent trial supervisors recommended the continuation of a separate phase III trial, OCEANIC-STROKE, testing asundexian to prevent repeated strokes in participants who have already suffered one.

Persons: Wolfgang Rattay, Germany's Bayer, Bill Anderson, Bayer, Stefan Oelrich, Johnson, Ludwig Burger, Jose Joseph, Miranda Murray, Christopher Cushing Organizations: Bayer AG, REUTERS, Bristol, Myers Squibb, Johnson, Thomson Locations: Wuppertal, Germany, United States, asundexian, U.S, Frankfurt, Bengaluru

☆ Xi tells US firms China ready to be partner and friend
▼ + stars: | 2023-11-16 | by ( Michael Martina | ) www.reuters.com time to read: +5 min

Xi received a standing ovation as he entered the room, and two more before and after he took the stage to speak. "Whatever stage of development it may reach, China will never pursue hegemony or expansion, and will never impose its will on others. China does not seek spheres of influence, and will not fight a cold war or a hot war with anyone," Xi said. China and the U.S. reached an agreement to curb fentanyl production in earlier talks between Xi and Biden. Analysts have said Xi's speech alone is unlikely to dramatically alter U.S. business sentiment about China.

Persons: Xi Jinping, Carlos Barria, Xi, Joe Biden, Biden, Tim Cook, Laurence Fink, Broadcom's, Hock Tan, Ray Dalio, Albert Bourla, Gina Raimondo, Mike Gallagher, Gallagher, Gary Dvorchak, Dvorchak, Michael Martina, Valerie Insinna, Stephen Nellis, Lisa Baertlein, Niket, Ethan Wang, Liz Lee, Stephen Coates Organizations: National Committee, China Relations, China Business Council, Economic Cooperation, REUTERS, Apple, BlackRock, Pfizer, SAN FRANCISCO, U.S, Beijing, Congress, Bridgewater Associates, Commerce, U.S . House, Representatives, Muslim, U.S ., Communist Party, Thomson Locations: Asia, San Francisco , California, U.S, China, United States, San Francisco, Beijing, Washington, China . U.S, Iowa

☆ Pfizer to cut 500 jobs at UK site as part of wider cost cuts
▼ + stars: | 2023-11-14 | by ( ) www.reuters.com time to read: +1 min

Pfizer company logo is seen at a Pfizer office in Puurs, Belgium, December 2, 2022. REUTERS/Johanna Geron/ File Photo Acquire Licensing RightsNov 14 (Reuters) - Pfizer (PFE.N) will cut 500 jobs at its Sandwich, Kent site in the U.K. as part of its $3.5 billion cost-cutting plan, the drugmaker said on Tuesday. The U.S. drugmaker announced the cost-cutting program in October after slashing its full-year revenue forecast due to lower-than-expected sales of its COVID-19 vaccine and treatment. Pfizer, which employs roughly 83,000 people globally, has not disclosed how many jobs will be affected by the cost-reduction program. The company said on Tuesday it would share further details on the program as part of the full-year forecast for 2024.

Persons: Johanna Geron, drugmaker, Christy Santhosh, Shailesh Kuber Organizations: Pfizer, REUTERS, Thomson Locations: Puurs, Belgium, Sandwich, Kent, U.S

☆ Pfizer wants in on the weight loss drug market – and upcoming data will be crucial for its success
▼ + stars: | 2023-11-13 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +2 min

As its Covid gains evaporate, Pfizer wants a chunk of the budding weight loss drug market. Those companies helped spark the weight loss drug industry gold rush over the last year with their weekly obesity and diabetes injections, such as Novo Nordisk's Wegovy and Ozempic and Eli Lilly's Mounjaro. They want to see the drug cause a similar level of weight loss as a once-daily pill from Eli Lilly. "If Pfizer's data is positive, then I think people might be able to look beyond all this Covid overhang," Cantor Fitzgerald analyst Louise Chen told CNBC. A weight loss pill could be a boon for all three companies.

Persons: Eli Lilly, Eli Lilly's Mounjaro, Albert Bourla, –, Cantor Fitzgerald, Louise Chen Organizations: Pfizer, Novo Nordisk, Nordisk's Wegovy, CNBC

☆ Chart Master: Sell healthcare, hold off on buying Pfizer
▼ + stars: | 2023-11-10 | by ( ) www.cnbc.com time to read: 1 min

In this videoShare Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailChart Master: Sell healthcare, hold off on buying PfizerCarter Worth, Worth Charting, joins 'Fast Money' to talk his take on the healthcare space, Pfizer's recent performance and more.

Persons: Pfizer Carter Worth Organizations: Pfizer

☆ An Airbnb host whose SF duplex was flooded by a guest says she only got enough compensation to 'make a difference' after posting on X
▼ + stars: | 2023-11-05 | by ( Lakshmi Varanasi | ) www.businessinsider.com time to read: +7 min

Erika Gemzer says her Airbnb guests flooded her San Francisco duplex, leaving her $300,000 in debt. She posted a thread on X six months later, criticizing Airbnb for its compensation offer. AdvertisementAdvertisementSix months after Airbnb host Erika Gemzer's duplex in San Francisco was flooded, she took to social media to confront the vacation rental company. Here's the story of how I ended up pregnant and homeless and in over $300,000 of debt after Airbnb guests flooded my home. While the new amount doesn't cover everything, it covers enough to "make a difference," Gemzer told Insider via text.

Persons: Erika Gemzer, Airbnb, Gemzer, —, Erika Gemzer's, rika, ake, emzer, rika G emzer, ince, ingle, lanning, ike Organizations: Service, ust Locations: Francisco, San Francisco

☆ Pfizer swings to quarterly loss as COVID product demand slump sparks charges
▼ + stars: | 2023-10-31 | by ( ) www.reuters.com time to read: +3 min

The company recorded a $5.6 billion charge in the third quarter related to Paxlovid and vaccine Comirnaty, most of which was disclosed earlier this month. Paxlovid sales slumped 97% in the third quarter to $202 million, while vaccine revenue came in at $1.31 billion, down from $4.4 billion a year earlier. Analysts had expected sales of $1.44 billion for the vaccine and $618.20 million for Paxlovid, according to LSEG data. Sales of its recently launched respiratory syncytial virus (RSV) vaccine, Abrysvo, came in at $375 million for the quarter. Overall revenue was $13.23 billion, compared to $22.64 billion a year earlier.

Persons: Wolfgang Rattay, Evan Seigerman, Bhanvi Satija, Michael Erman, Sriraj Organizations: REUTERS, Pfizer, U.S, BioNTech, Analysts, BMO Capital, U.S ., Thomson Locations: Bengaluru, New York

Six of the 11 major S&P 500 sectors were trading lower, with information technology (.SPLRCT) leading losses. Pfizer's shares (PFE.N) fell 1.5% after the drugmaker reported its first quarterly loss since 2019. U.S. equities are tracking their third straight month in the red, with the S&P 500 (.SPX) and the Nasdaq (.IXIC) on course for their worst October since 2018. The Fed kicks off a two-day monetary policy meeting on Tuesday. The Fed's commentary on Wednesday would be crucial in assessing how long monetary policy could stay restrictive amid recent signs of economic strength.

Persons: Brendan McDermid, Andrew Hunter, Amruta Khandekar, Shashwat Chauhan, Saumyadeb Chakrabarty, Shounak Dasgupta, Maju Samuel Organizations: New York Stock Exchange, REUTERS, Corp, Dow, Nasdaq, Federal, Nvidia, Microsoft, Caterpillar, Chicago PMI, Capital Economics, Dow Jones, PDD Holdings, VF Corp, Vans, Arista Networks, Sarepta Therapeutics, NYSE, Thomson Locations: New York City, U.S, China, Bengaluru

☆ 'We are really keen to join forces with Seagen': Pfizer CEO on plans to acquire cancer drugmaker
▼ + stars: | 2023-10-31 | by ( Julie Coleman | ) www.cnbc.com time to read: +1 min

Pfizer CEO Albert Bourla discussed his company's plans to acquire cancer drugmaker Seagen in a Tuesday interview with CNBC's Jim Cramer. "We are really keen to join forces with Seagen," Bourla said. "We are going to kill cancer." The company plans to acquire Seagen in a $43 billion deal, and Bourla said he is "optimistic" it will close by year-end or early next year. Seagen is known for its antibody-drug conjugate treatments, which aim to kill only cancer cells, not healthy ones.

Persons: Albert Bourla, CNBC's Jim Cramer, Bourla Organizations: Pfizer, Federal Trade Commission, European Commission, CNBC Locations: U.S

Paxlovid, Pfizer's anti-viral medication to treat the coronavirus disease (COVID-19), is displayed in this picture illustration taken October 7, 2022. Sales of Paxlovid and the vaccine Pfizer makes with German partner BioNTech (22UAy.DE) had boosted revenue to record levels the last two years. Reuters GraphicsPfizer continues to expect 2023 revenue growth of 6%-8% from non-COVID products, with a majority occurring in the second half. Paxlovid sales slumped 97% in the third quarter to $202 million, while vaccine revenue of $1.31 billion was down from $4.4 billion a year earlier. Analysts had expected $1.44 billion for the vaccine and $618.20 million from Paxlovid, according to LSEG data.

Persons: Wolfgang Rattay, Evan Seigerman, BioNTech, Albert Bourla, Angela Hwang, Paxlovid, Bhanvi Satija, Michael Erman, Sriraj Kalluvila, Bill Berkrot Organizations: REUTERS, Pfizer, BMO Capital, Reuters Graphics Pfizer, GSK, CVS, Analysts, U.S ., Thomson Locations: Europe, Paxlovid, Bengaluru, New York

“Just trying to make the play,” Seager said. YOUNG AND CLEAN(UP)Texas' Evan Carter became the fourth-youngest player to hit cleanup in a World Series game at 21 years, 62 days. BEEN A WHILEThis was the first World Series game played at Chase Field since Nov. 4, 2001, when the Diamondbacks beat the Yankees 3-2 in Game 7 after Luis Gonzalez's walk-off hit against Mariano Rivera clinched the series. The D-backs lost Monday for the first time in the World Series at Chase Field. BIG SWINGThere have been 62 previous instances in World Series history when the series was tied at 1-1 after Game 2.

Persons: — Corey Seager, Max Scherzer, Scherzer, Adolis, “ We’re, ” Seager, “, Seager —, —, Brandon Pfaadt, Christian Walker, García, Jon Gray, Josh Sborz, Aroldis Chapman, José Leclerc, ”, Marcus Semien, “ Adolis, haven’t, ” Gray, Leclerc, Gray, Emmanuel Rivera, Chapman, Geraldo Perdomo, Corbin Carroll, Seager, Ketel, Marcus, Walker, Pfaadt, Tommy Pham, Tony Perezchica, Torey Lovullo, Alek Thomas, Josh Jung, Thomas, he'll, Evan Carter, Bruce Bochy, Carter, Miguel Cabrera, Ty Cobb, Juan Soto, Luis Gonzalez's, Mariano Rivera, Lovullo, “ Don Drysdale, “ It’s, ” Drysdale, of Famer Sandy Koufax, Bochy, ___ Organizations: PHOENIX, Texas Rangers, Arizona Diamondbacks, Chase, Diamondbacks, Chase Field, Ketel Marte, Rangers, Yankees, NEXT, Los Angeles Dodgers, of Famer, Dodgers Locations: Texas, Arizona, ” Texas, Semien, Southern California

☆ Pfizer RSV vaccine lags GSK’s as head-to-head competition underway
▼ + stars: | 2023-10-30 | by ( Michael Erman | ) www.reuters.com time to read: +4 min

[1/3] View of Pfizer's new respiratory syncytial virus (RSV) vaccine Abrysvo during its manufacture in this undated handout picture. "800 POUND GORILLAS"CVS, which has more than 9,000 U.S. locations, declined to comment on why it was only carrying GSK's vaccine. It was not immediately clear how many RSV shots were being administered in pharmacies versus doctors' offices. GSK declined to discuss its RSV vaccine contracts, but said customer relationships gives it a competitive advantage. Two independent pharmacists said they are being charged a lower price by wholesalers for the GSK vaccine, which comes in boxes of 10.

Persons: Price, Ben Link, Link, Pfizer's, Dovato, Morningstar, Damien Conover, We’ve, Alison Hunt, Michelle Vargas, Michael Erman, Caroline Humer, Bill Berkrot Organizations: Pfizer, Handout, REUTERS, GSK, Reuters, CVS Health, CVS, Walgreens, Walmart, Aid, Thomson Locations: United States, British, U.S, South Carolina

The government has been overseeing distribution of the treatments, alongside vaccines and tests, but has transferring that work to traditional commercial channels. Commercial ordering for the treatments is set to start on Nov. 1. Returns will begin on Nov. 15, the official said, and will be accepted through the end of the year. The government is recommending returns start in December enough time for the establishment of patient assistance programs and securing of commercially-labeled doses. Reporting by Ahmed Aboulenein Editing by Marguerita ChoyOur Standards: The Thomson Reuters Trust Principles.

Persons: Lagevrio, Ahmed Aboulenein, Marguerita Choy Organizations: U.S, Pfizer, Paxlovid, U.S . Department of Health, Human Services, Thomson Locations: U.S

☆ US Shifting COVID Antivirals to Commercial Market on Nov. 1
▼ + stars: | 2023-10-27 | by ( Oct. | At P.M. | ) www.usnews.com time to read: +2 min

The government has been overseeing distribution of the treatments, alongside vaccines and tests, but has transferring that work to traditional commercial channels. Commercial ordering for the treatments is set to start on Nov. 1. The U.S. government paid around $530 per course for Paxlovid, the most commonly prescribed at home COVID-19 treatment in the country, and made it available at no cost. Returns will begin on Nov. 15, the official said, and will be accepted through the end of the year. The government is recommending returns start in December enough time for the establishment of patient assistance programs and securing of commercially-labeled doses.

Persons: Ahmed Aboulenein WASHINGTON, Lagevrio, Ahmed Aboulenein, Marguerita Choy Organizations: U.S, Pfizer, Paxlovid, U.S . Department of Health, Human Services Locations: U.S

WASHINGTON (AP) — The COVID-19 treatments millions of Americans have taken for free from the federal government will enter the private market next week with a hefty price tag. Pharmaceutical giant Pfizer is setting the price for a five-day treatment of Paxlovid at $1,390, but Americans can still access the pills at no cost -- for now. The less commonly used COVID-19 treatment Lagevrio, manufactured by Merck, also will hit the market next week. People on private insurance may start to notice copays for the treatments once their pharmacy or doctor's office runs out of the COVID-19 treatments they received from the government. Full-year revenue for Paxlovid and Pfizer's COVID-19 vaccine, Comirnaty, is expected to be approximately $12.5 billion.

Persons: “ Pfizer, Paxlovid, coronavirus, Pfizer's, “, Tom Murphy Organizations: WASHINGTON, Pharmaceutical, Pfizer, Merck, Health, Human Services, The Department of Veterans Affairs, Department of Defense, Indian Health Service, U.S, Associated Press, and Drug Administration, Paxlovid Locations: U.S, Indianapolis

☆ Merck quarterly profit tops expectations on COVID pill surprise
▼ + stars: | 2023-10-26 | by ( Michael Erman | ) www.reuters.com time to read: +2 min

The Merck logo is seen at a gate to the Merck & Co campus in Rahway, New Jersey, U.S., July 12, 2018. Merck raised Lagevrio full-year sales forecast to $1.3 billion. Third-quarter sales of Merck's top-selling cancer immunotherapy, Keytruda, stood at $6.34 billion, surpassing analysts' average estimate of $6.22 billion. Gardasil, its vaccine to prevent cancers caused by human papillomavirus (HPV), generated sales of $2.59 billion, rising 13% but missing analysts' average estimate of $2.69 billion. The company posted sales of $15.96 billion in the reported quarter, compared to the average analyst estimate of $15.3 billion.

Persons: Brendan McDermid, Molnupiravir, Merck, Wells, Mohit Bansal, drugmaker, Michael Erman, Leroy Leo, Bill Berkrot Organizations: Merck, Co, REUTERS, Merck & Co, Pfizer's, Thomson Locations: Rahway , New Jersey, U.S, Japan, United States, EU

☆ Pfizer's combination Covid, flu vaccine will move to final-stage trial after positive data
▼ + stars: | 2023-10-26 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +2 min

Pfizer on Thursday said its combination vaccine candidates targeting Covid and the flu will move to a final-stage trial in the coming months after showing positive initial results in an early to mid-stage study. Covid vaccine rates in the U.S. were bleak last year, and could look the same this year. The trial measured the safety, tolerability and efficacy of Pfizer's combination vaccine candidates among adults ages 18 to 64. The results showed that "lead" formulations of Pfizer's combination vaccine demonstrated robust immune responses to influenza A, influenza B and Covid strains, according to Pfizer. The safety profiles of the combination vaccine candidates were also consistent with the company's Covid vaccine.

Persons: BioNTech, Annaliesa Anderson, Pfizer's, Albert Bourla Organizations: Pfizer, BioNTech, Moderna Locations: U.S

☆ Debunking claims that a 'cartel' of asset managers controls major U.S. corporations
▼ + stars: | 2023-10-23 | by ( Ryan Ermey | ) www.cnbc.com time to read: +2 min

If you look up the top institutional investors in these firms, you will find major asset managers close to the top of the list. 2, and State Street is No. State Street, Vanguard and BlackRock are the top shareholders in Lockheed, in that order. Pfizer's top shareholders: Vanguard, BlackRock and State Street. That's because BlackRock makes money by collecting fees from its investors, not by reaping profits from the companies it invests in.

Persons: Lockheed Martin, Daniel Sotiroff Organizations: Apple, Lockheed, Pfizer, Vanguard, BlackRock, Morningstar Research Services, State Locations: BlackRock

HOUSTON (AP) — Max Scherzer is set to pitch another Game 7 in Houston with visiting teams undefeated in the series. Texas also won Games 1 and 2 in Houston. Cristian Javier, the Game 3 winner when the defending World Series champion Astros won 8-5, will pitch again for Houston. The 26-year-old right-hander is 6-1 with a 2.08 ERA in 16 postseason games, winning all four of his starts. You look at matchups and things like that, but they’re all ready to go.”Scherzer will be making his 24th postseason start for five different teams.

Persons: — Max Scherzer, Max, Scherzer, Cy Young, ”, Nathan Eovaldi, “ He’s, Cristian Javier, ” Javier, It’s, Nate, Bruce Bochy, “, David Wells, ___ Organizations: HOUSTON, Texas Rangers, Washington, Nationals, Astros, The Rangers, Houston, Rangers, New York Mets, ” Rangers, Detroit, Los Angeles Dodgers, Yankees Locations: Houston, Texas, Arlington, Detroit , Washington, Cincinnati, Baltimore, Boston, San Diego

☆ Pfizer to price Covid drug Paxlovid at $1,390 per course
▼ + stars: | 2023-10-18 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +2 min

Pfizer will price a five-day course of its Covid antiviral drug Paxlovid at $1,390 when the company starts to transition it to the commercial market later this year. A company spokesperson on Wednesday confirmed the price, which was first reported by The Wall Street Journal. But beginning in 2024, Pfizer will sell Paxlovid directly to health insurers, which comes as demand for Covid vaccines and treatments slumps nationwide. But health insurance plans will likely pay much less than the nearly $1,400 list price for Paxlovid, meaning patients will probably have small or no out-of-pocket costs. Overall, Pfizer now expects 2023 sales of $58 billion to $61 billion, down from its previous guidance of $67 billion to $70 billion.

Persons: Angelica Peebles Organizations: Pfizer, Wednesday, Wall Street, Paxlovid, FDA, CNBC Locations: Paxlovid

☆ Pfizer to price COVID treatment Paxlovid at $1,390 per course
▼ + stars: | 2023-10-18 | by ( Michael Erman | ) www.reuters.com time to read: +3 min

The new list price, which does not include rebates and other discounts to insurers and pharmacy benefit managers, is $1,390 per course, Pfizer said in an emailed statement. The U.S. government paid around $530 per course for Paxlovid it has made available to Americans at no cost. The United States purchased around 24 million courses of the oral two-drug treatment from Pfizer, and still had a large supply, but arranged to return 7.9 million courses last week. In 2022, patients were given around 7 million courses of the drug, according to U.S. government data. Through Oct. 1, around 3.4 million courses had been administered in 2023.

Persons: Wolfgang Rattay, Paxlovid, Michael Erman, Bill Berkrot Organizations: REUTERS, Pfizer, for Clinical, Economic, United, Wall Street, Thomson Locations: U.S, United States, Maplewood , N.J

☆ Pfizer, BioNTech shares fall on lower COVID product sales forecast
▼ + stars: | 2023-10-16 | by ( Ludwig Burger | ) www.reuters.com time to read: +2 min

REUTERS/Dado Ruvic/File photo Acquire Licensing RightsOct 16 (Reuters) - Shares of Pfizer (PFE.N) and German partner BioNTech (22UAy.DE) fell on Monday after the U.S. drugmaker slashed the sales forecast for its COVID vaccine and therapy last week, and some analysts said the reduction was bigger than expectations. The COVID sales forecast cut was bigger than expected, Wells Fargo analyst Mohit Bansal said, adding that Wall Street's COVID sales estimates for the next few years may come down. Shares in BioNTech, which is also developing cancer treatments, were down 6.7% at a two-month low in Frankfurt. Its U.S.-listed shares fell 6.8% in premarket trading, while Pfizer's shares fell 2%. The news also dragged down shares of rival COVID vaccine maker Moderna (MRNA.O) by 4.7%.

Persons: Dado, BioNTech, drugmaker, Wells, Mohit Bansal, Ludwig Burger, Rachel More, Miranda Murray, Jason Neely, Shounak Organizations: COVID, Institute for Health, Food, REUTERS, Pfizer, U.S, Its U.S, Moderna, Manas Mishra, Thomson Locations: Zenica, Bosnia, Herzegovina, Wells Fargo, BioNTech, Frankfurt, Its, Bengaluru

☆ Pfizer gets upgrade at Jefferies, which says there's a buying opportunity in the pharma giant's stock
▼ + stars: | 2023-10-16 | by ( Brian Evans | ) www.cnbc.com time to read: +1 min

Jefferies thinks its time for investors to go long on Pfizer . "In our view, PFE has one of the most intriguing catalyst paths over the next yr in large cap pharma and trades ~15% below where it traded at the start of the COVID pandemic." The analyst added Pfizer has already presented "an impressive innovation framework" that has helped the company adapt to healthcare headwinds, which underpinned the bullish long-term view. "During the pandemic, Pfizer in collaboration with Biontech rolled out COVID vaccines in a historical timeframe. PFE YTD mountain Pfizer stock YTD — CNBC's Michael Bloom contributed to this report.

Persons: Jefferies, Akash Tewari, it's, Tewari, PFE, Biontech, Paxlovid, Michael Bloom Organizations: Pfizer, pharma

Search resuls for: "Zer's"

25 mentions found